Fig. 6 | Nature Communications

Fig. 6

From: Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

Fig. 6

mRNA sequencing of flank and intracranial (IC) tumor tissues from animals dosed with erlotinib showing dose-dependent pathway regulation. a Summary of pathways regulated by different doses of erlotinib in flank tumors (n = 5), z-Scores of significant pathways relative to placebo are presented. b MALDI MS images of erlotinib in brain tissue with IC tumor and regions of interest (R1, R2, L1 and L2) used for laser capture microdissection (LCM) and subsequent mRNA sequencing, adjacent section with H&E staining and optical image of adjacent section used for LCM. c Average (mean) relative intensity of erlotinib (m/z 394.176) detected in each ROI of MALDI MS ion image. d Clustermap of transcripts from flank and IC tumors by mRNA sequencing

Back to article page